Advancing pathology and cancer research with next-generation sequencing | Illumina Video

24 November 2015

NGS is setting a new standard in cancer research. http://www.illumina.com/applications/cancer/clinical-cancer-research.html Dr. Platt of MPLN shares her experience, using molecular assays in clinical research, and discusses how MPLN uses NGS to further their oncology and research portfolio. She shares case examples of the molecular usability and analysis options for deep sequencing of tumor samples. Illumina continues to collaborate with leading laboratories to provide focused, complete solutions, powered by NGS. Presenter Dr. Jamie Platt Vice President, Genomic Solutions Molecular Pathology Laboratory Network, Inc. Subscribe to the Illumina video channel. http://www.youtube.com/subscription_center?add_user=IlluminaInc

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.